» Articles » PMID: 7687622

Episialin (MUC1) Inhibits Cytotoxic Lymphocyte-target Cell Interaction

Overview
Journal J Immunol
Date 1993 Jul 15
PMID 7687622
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Episialin (MUC1) is a mucin-like glycoprotein abundantly expressed on most carcinoma cells. As a result of its extended and rigid structure, it reduces intercellular adhesion. We investigated whether this antiadhesion function allows tumor cells expressing high levels of episialin to escape from immune recognition. To test this hypothesis, we transfected episialin-negative (episialin-) melanoma cells (A375) with the MUC1 cDNA-encoding episialin. The results demonstrated that episialin-positive (episialin+) melanoma cells were significantly less susceptible to lysis than episialin- melanoma cells by both alloantigen or rIL-2-stimulated cytotoxic effector cells. In addition, cold target inhibition experiments with episialin+ and episialin- cells clearly demonstrated preferential lysis of episialin- cells. Furthermore, antibody blocking studies showed that lysis of episialin+, but not of episialin-, melanoma cells was predominantly dependent on the leukocyte function-associated Ag-1/intracellular adhesion molecule adhesion route, suggesting that episialin+ target cells adhere less efficiently to effector cells than episialin- target cells. This notion was supported by the observation that conjugate formation of the effector cells with episialin+ target cells was significantly impaired. From these results we conclude that over-expression of episialin as found on many tumor cells may indeed affect efficient lysis by cytotoxic lymphocytes and thus may contribute to escape from immune surveillance.

Citing Articles

Immunoengineering can overcome the glycocalyx armour of cancer cells.

Park S, Colville M, Paek J, Shurer C, Singh A, Secor E Nat Mater. 2024; 23(3):429-438.

PMID: 38361041 PMC: 11471287. DOI: 10.1038/s41563-024-01808-0.


Cancer immune exclusion: breaking the barricade for a successful immunotherapy.

Bruni S, Mercogliano M, Mauro F, Cordo Russo R, Schillaci R Front Oncol. 2023; 13:1135456.

PMID: 37284199 PMC: 10239871. DOI: 10.3389/fonc.2023.1135456.


Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS).

Buyuk M, Ozluk Y, Bakkaloglu D, Ozkan B, Firat P, Yilmazbayhan D Turk Patoloji Derg. 2022; 39(1):64-74.

PMID: 36367122 PMC: 10518128. DOI: 10.5146/tjpath.2022.01593.


Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.

Lee D, Choi S, Park Y, Jin H Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681277 PMC: 8537522. DOI: 10.3390/ph14101053.


Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression.

Marimuthu S, Rauth S, Ganguly K, Zhang C, Lakshmanan I, Batra S Cancer Metastasis Rev. 2021; 40(2):575-588.

PMID: 33813658 PMC: 9635594. DOI: 10.1007/s10555-021-09959-1.